1,721,400 research outputs found
Diagnosis of Helicobacter pylori: invasive and non- invasive testsRicci C, Holton J, Vaira D
No full textHelicobacter pylori infection can be diagnosed by invasive techniques requiring endoscopy and biopsy (e.g. histological examination, culture and rapid urease test) and by non-invasive techniques, such as serology, the urea breath test, urine/blood or detection of H. pylori antigen in stool specimen. Some
non-invasive tests, such as the urea breath test and the stool antigen test, detect active infection: these are called ‘active tests’. Non-invasive tests (e.g. serology, urine, near-patient tests) are markers of exposure to H. pylori but do not indicate if active infection is ongoing; these are ‘passive tests’. Non-invasive test-and-treat strategies are widely recommended in the primary care setting. The choice of appropriate test depends on the pre-test probability of infection, the characteristics of the test being used and its cost-effectivenes
Urease Tests for Campytobacter pytori Detection
No full textUrease Tests for Campytobacter pytori Detectio
Vector potential of houseflies (Musca domestica) for Helicobacter pylori
No full textVector potential of houseflies (Musca domestica) for Helicobacter pylor
Serum immunoglobulin G antibody levels for Campylobacter pylori diagnosis
No full textSerum immunoglobulin G antibody levels for Campylobacter pylori diagnosi
Vector potential of houseflies (Musca domestica) for Helicobacter pylori
No full textVector potential of houseflies (Musca domestica) for Helicobacter pylor
Diagnosis of Helicobacter pylori: Invasive and non invasive tests.
No full textHelicobacter pylori infection can be diagnosed by invasive techniques requiring endoscopy and biopsy
(e.g. histological examination, culture and rapid urease test) and by non-invasive techniques, such as
serology, the urea breath test, urine/blood or detection of H. pylori antigen in stool specimen. Some
non-invasive tests, such as the urea breath test and the stool antigen test, detect active infection:
these are called ‘active tests’. Non-invasive tests (e.g. serology, urine, near-patient tests) are markers
of exposure to H. pylori but do not indicate if active infection is ongoing; these are ‘passive tests’.
Non-invasive test-and-treat strategies are widely recommended in the primary care setting. The
choice of appropriate test depends on the pre-test probability of infection, the characteristics of
the test being used and its cost-effectiveness
Helibacter pylori and gastroduodenal disease
No full textHelicobacter pylori infection is now recognised to produce antral gastritis and possibly to be an aetiological factor contributing to duodenal ulceration. It has a number of virulence factors which could be relevant to the induction of inflammation and ulceration, but further work is needed to elucidate which of these factors is clinically relevant. There are a number of diagnostic tests for this organism, and the optimal combination of tests, in different clinical settings, is yet to be determined. The optimal drug regimen for the eradication of H. pylori is uncertain, but acceptable cure rates can be achieved with a combination of antibiotics and bismuth salts. New agents are being developed and assessed. Other important questions still to be answered relate to the epidemiology of this organism and its relationship, if any, to gastric cancer
Helibacter pylori and gastroduodenal disease
No full textHelicobacter pylori infection is now recognised to produce antral gastritis and possibly to be an aetiological factor contributing to duodenal ulceration. It has a number of virulence factors which could be relevant to the induction of inflammation and ulceration, but further work is needed to elucidate which of these factors is clinically relevant. There are a number of diagnostic tests for this organism, and the optimal combination of tests, in different clinical settings, is yet to be determined. The optimal drug regimen for the eradication of H. pylori is uncertain, but acceptable cure rates can be achieved with a combination of antibiotics and bismuth salts. New agents are being developed and assessed. Other important questions still to be answered relate to the epidemiology of this organism and its relationship, if any, to gastric cancer
- …
